Inclusion Criteria:

- Patients who have completed preceding gefitinib therapy from either the 1839IL/0709
(250mg dosing) study or 1839IL/0710 (250mg dosing) study and in the opinion of the
investigator may benefit from further gefitinib treatment.

- No more than 14 days lapse in gefitinib treatment between the patient completing the
preceding gefitinib clinical study and beginning of this study except when agreed by
the AstraZeneca physician.

Exclusion Criteria:

- Any evidence of clinically active interstitial lung disease (patients with
chronic,stable, radiographic changes who are asymptomatic need not be excluded).

- In the opinion of the investigator, any evidence of severe or uncontrolled systemic
disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal
disease).

- Withdrawal, at any time, from the preceding gefitinib study.

- Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's
Wort